# Oral-ATO for TP53-mutated Myeloid Malignancies

> **NCT06778187** · PHASE2 · RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 30 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Neoplasm
- Chronic Myelomonocytic Leukemia
- TP53 Gene Mutation
- Arsenic Trioxide

## Interventions

- **DRUG:** Oral arsenic trioxide

## Key facts

- **NCT ID:** NCT06778187
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2027-02
- **Final completion:** 2028-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06778187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06778187, "Oral-ATO for TP53-mutated Myeloid Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06778187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*